Archive for the ‘Girosa’ Category

Unfortunately, the Food and Drug Administration rejected approval of the pharmaceutical Flibanserin, which is designed to treat the decreased sexual desire of women. Flibanserin, sometimes known as either Girosa or ‘female Viagra’ was rejected 10 votes to 1 by an FDA Advisory Panel who claimed that the submitted data from the clinical trials had no considerably better effect than a placebo. As seen in this article we published, “Women who were under the effects of Flibanserin claimed to have had sexually satisfying events more often than before using the drug. In fact, a raise from 2.8 to 4.5 times a month was shown by the results.”

Paula Hillard, a gynecologist at the Stanford University School of Medicine is not convinced of the clinical meaningful benefit of Flibanserin. We, on the other hand, are quite assured of the positive benefits of Flibanserin, and believe that the FDA will eventually reconsider their decision. We believe Flibanserin will have the biggest impact on pre-menopausal women with Hypoactive Sexual Desire Disorder.

Flibanserin was elaborated by the German Company Boehringer Ingelheim and was promoted as a product capable of providing “satisfying sexual events” for pre-menopausal women with ‘Hypoactive Sexual Desire Disorder’ known as HSDD. Many individuals claim that HSDD does not exist, and that women may not suffer from any sort of sexual dysfunction, but instead that it is all in their heads. Therefore, the introduction of Flibanserin has sparked a lot of controversy in the pharmaceutical industry. Currently, Flibanserin / Girosa are not approved for sale in any country, but everyone is working hard to change this. Please stay tuned for additional updates and information.

Girosa is the thought to be proposed name of the Flibanserin drug, currently under clinical test by the Boehringer Ingelheim GmbH German pharmaceutical company. The product line is surrounded by great secrecy and little information is to be found on it. There is a very good reason for this secrecy, as it is anticipated that the market for this so-called female Viagra has a value of roughly $30 million dollars sales per year. The drug has been development and test for some years now, and it has been generally referred to as Flibanserin. However, according to some rumors, the official name of the product will be Girosa after its acceptance for us in the United States.

What is this drug?

Basically, Girosa is a non-hormonal drug consisting of dopamine or D4 cereptors and serotonin receptors also known as 5-HT. Paradoxically, it has been originally developed as an antidepressant, but it seems that when improvements in female sexual desire were reported, the company saw the opportunity for much higher profits in this specific area compared to the much crowded mood enhancer segment. This drug increases the dopamine level in the female body, which is to a certain degree responsible for libido and arousal and thus it might be helpful in pre-menopausal Hypo Sexual Desire Disorder – HSDD, or Female Sexual Dysfunction – FSD. Well, in any case that is the declared target market and objective of the end product.

Interestingly, Boehringer Ingelheim GmbH is not fully sure about how the positive effect on sexual desire arises from Flibanserin, but they are reposting positive results from all their four clinical tests that have involved more than 5,000 women in over 220 clinics across the world. As BioSante is planning to get FDA approval for LibiGel within the next 18 months, Boehringer is also expecting to have FDA approval for medical use in the United States in the near future. Targeting the women Viagra market, it is evident how a multi-million dollar industry for men can have a trickle effect on the market for women, especially if we take in consideration the estimation of scientist and doctors that around 40% of women in the United States experience some symptom of HSDD or FSD.